← Back to patent-cliff list
RBS-2418
Tier C — Watch / tradeRBS-2418
Riboscience LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：STING, ENPP1
Indications (approved)：Hepatocellular carcinoma, Colorectal cancer, Metastatic cancer
Regional status
US
Phase II
2025-01-17
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RBS-2418?
Approved indications include: Hepatocellular carcinoma, Colorectal cancer, Metastatic cancer.
When does the RBS-2418 patent expire?
No public expiry year is available for RBS-2418 yet; this page updates once verified.
How do I get a quote for RBS-2418 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01